Skip to content

Biosensor Platform Future Tests

Saliva Glucose Biosensor Global Epidemic

Leadership Media Investors FAQs Contact

Biosensor Platform Future Tests

Saliva Glucose Biosensor Global Epidemic

Leadership Media Investors FAQs Contact

News

GBS Inc. Announces Key Milestone in Prospective Study Comparing Glucose in Oral Fluids and Blood

Sign Up

Register for email alerts for the latest on the Biosensor Platform and GBS Inc.

Email
Name
This field is for validation purposes and should be left unchanged.

Privacy Policy Terms of Use

Certain statements in this website may constitute “forward-looking” statements as defined in Section 27A of the Securities Act of 1933, as amended (the “Securities Act”), Section 21E of the Securities Exchange Act of 1934 (the “Exchange Act”), the Private Securities Litigation Reform Act of 1995 (the “PSLRA”) or in releases made by the Securities and Exchange Commission (“SEC”), all as may be amended from time to time. Such forward-looking statements involve known and unknown risks, uncertainties and other important factors that could cause the actual results, performance or achievements of GBS, Inc. and its affiliates (“GBS”) or industry results, to differ materially from any future results, performance or achievements expressed or implied by such forward-looking statements. Statements that are not historical fact are forward-looking statements. Forward-looking statements can be identified by, among other things, the use of forward-looking language, such as the words “plan,” “believe,” “expect,” “anticipate,” “intend,” “estimate,” “project,” “may,” “will,” “would,” “could,” “should,” “seeks,” or “scheduled to,” or other similar words, or the negative of these terms or other variations of these terms or comparable language, or by discussion of strategy or intentions. These cautionary statements are being made pursuant to the Securities Act, the Exchange Act and the PSLRA with the intention of obtaining the benefits of the “safe harbor” provisions of such laws.

GBS cautions that any forward-looking statements made by GBS are not guarantees or indicative of future performance. Although GBS believes that its plans, cost estimates, returns on investments, intentions and expectations reflected in or suggested by such forward-looking statements are reasonable, actual results could differ materially from a projection or assumption in any forward-looking statements. GBS’s future financial condition and results of operations, as well as any forward-looking statements, are subject to change and to inherent risks and uncertainties. GBS does not have, or undertake, any obligation to update or revise any forward-looking statements whether as a result of new information, subsequent events or otherwise, unless otherwise required by law.

These materials are not intended as an offer or solicitation with respect to the purchase or sale of any security and may not be reproduced or redistributed in whole or in part to any other person. Recipients should seek appropriate independent professional advice prior to relying on, or entering into any commitment based upon materials.

All information included in this website is based on continuing operations, unless otherwise noted.

Saleshttps://gbs.inc

420 Lexington Ave, Suite 300New YorkNY10170us

GBS Inc.Real-time, point-of-care testing at the tip of your tongueinfo@gbs.inc2067https://gbs.inc © Copyright 2022 GBS Inc. All rights reserved.